Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC (RARE)
My previous session
Most popular
  Report  
Delayed Quote. Delayed  - 01/18 04:00:00 pm
53.34 USD   +3.47%
2014Amid Alibaba fever, reasons for caution in IPO market
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Ultragenyx: 3Q Earnings Snapshot

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/05/2018 | 04:17pm EST

NOVATO, Calif. (AP) _ Ultragenyx Pharmaceutical Inc. (RARE) on Monday reported a loss of $87.3 million in its third quarter.

On a per-share basis, the Novato, California-based company said it had a loss of $1.74.

The results topped Wall Street expectations. The average estimate of 11 analysts surveyed by Zacks Investment Research was for a loss of $1.94 per share.

The biotechnology company posted revenue of $11.8 million in the period, which also topped Street forecasts. Nine analysts surveyed by Zacks expected $11.2 million.

Ultragenyx shares have increased 14 percent since the beginning of the year. In the final minutes of trading on Monday, shares hit $53.10, a climb of 7 percent in the last 12 months.

This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on RARE at https://www.zacks.com/ap/RARE

Automated Insights, source Associated Press News

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ULTRAGENYX PHARMACEUTICAL
01/15ULTRAGENYX PHARMACEUTICAL INC. : Entry into a Material Definitive Agreement (for..
AQ
01/07ULTRAGENYX PHARMACEUTICAL INC. : Regulation FD Disclosure, Other Events, Financi..
AQ
01/07Flurry of management moves on eve of JPM
AQ
01/05ULTRAGENYX PHARMACEUTICAL : Announces Positive Topline Results from First Cohort..
AQ
01/04Ultragenyx Announces Positive Topline Results from First Cohort of Phase 1/2 ..
GL
01/03Ultragenyx to Present at J.P. Morgan Healthcare Conference
GL
2018Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita (buros..
AQ
2018Ultragenyx and Kyowa Kirin Announce Health Canada Approval of Crysvita™..
GL
2018ULTRAGENYX PHARMACEUTICAL : Announces Intent to Submit New Drug Application to U..
AQ
2018ULTRAGENYX PHARMACEUTICAL INC. : Other Events, Financial Statements and Exhibits..
AQ
More news
Financials ($)
Sales 2018 49,6 M
EBIT 2018 -376 M
Net income 2018 -202 M
Finance 2018 286 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales 2018 48,6x
EV / Sales 2019 24,5x
Capitalization 2 698 M
Chart ULTRAGENYX PHARMACEUTICAL INC
Duration : Period :
Ultragenyx Pharmaceutical Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ULTRAGENYX PHARMACEUTICAL
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 70,7 $
Spread / Average Target 33%
EPS Revisions
Managers
NameTitle
Emil D. Kakkis President, Chief Executive Officer & Director
Daniel G. Welch Non-Executive Chairman
Wladimir Hogenhuis Chief Operating Officer
Shalini Sharp Chief Financial Officer & Executive Vice President
Dennis Karl Huang Chief Technical Operations Officer & Senior VP
Sector and Competitors
1st jan.Capitalization (M$)
ULTRAGENYX PHARMACEUTICAL INC22.68%2 698
GILEAD SCIENCES10.60%89 493
VERTEX PHARMACEUTICALS14.97%49 757
REGENERON PHARMACEUTICALS11.75%44 532
GENMAB-4.59%9 536
NEUROCRINE BIOSCIENCES, INC.28.18%8 300